Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Tolterodine Tartrate). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Detrusin LA is indicated for treating an overactive bladder, with symptoms such as urge urinary incontinence, urgency, and frequency.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Extended-release capsule: The recommended dose is Tolterodine Tartrate 4 mg once daily. Based on individual response and tolerability, the dose may be lowered to 2 mg once daily. For patients with significantly reduced hepatic or renal function, or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose is Tolterodine Tartrate 2 mg daily. Film-coated tablet: The recommended dose is Tolterodine Tartrate 2 mg twice daily, except in patients with impaired liver function or severely impaired renal function (GFR under 30 ml/min), for whom the recommended dose is one Tolterodine Tartrate 1 mg tablet twice daily. If side effects become troublesome, the dose may be reduced from 2 mg to 1 mg twice daily. The effect of treatment should be re-evaluated after 2 to 3 months. Pediatric use: The safety and effectiveness of tolterodine in children have not been established. Geriatric use: No overall differences in safety were observed between older and younger patients treated with Tolterodine.
পার্শ্বপ্রতিক্রিয়া
Dry mouth, headache, constipation, and abdominal pain were the side effects most often reported in patients taking Detrusin LA. Dry mouth was the single most common complaint, occurring in about 23.4% of patients on Detrusin LA tablets compared with 7.7% on placebo. As with other antimuscarinic medicines, Detrusin LA can also be expected to cause dry mouth, constipation, blurred or abnormal vision (from accommodation abnormalities), difficulty passing urine, and dry eyes. These side effects were recorded regardless of whether they were actually caused by the drug.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Detrusin LA should be used with caution in patients who have significant bladder outflow obstruction, since it can raise the risk of urinary retention, and in patients with gastrointestinal obstructive conditions such as pyloric stenosis, since it can raise the risk of gastric retention. Caution is also needed in patients being treated for narrow angle glaucoma. Patients with significantly reduced liver function or kidney function should be given the recommended dose of Detrusin LA at 2 mg daily. In a study looking at the effect of Detrusin LA immediate release tablets on the QT interval, the effect appeared greater at 8 mg per day, twice the therapeutic dose, than at 4 mg per day, and it was more pronounced in CYP2D6 poor metabolizers than in extensive metabolizers. The effect seen with Detrusin LA at 8 mg per day was not as large as that observed after four days of therapeutic dosing with the active control moxifloxacin, though the confidence intervals overlapped. These findings should be kept in mind when deciding whether to prescribe Detrusin LA tablets to patients with a known history of QT prolongation or to patients taking Class IA antiarrhythmic medications such as quinidine or procainamide, or Class III antiarrhythmic medications such as amiodarone or sotalol. Patients should be told that antimuscarinic agents such as Detrusin LA tablets may cause blurred vision, dizziness, or drowsiness.
নিষেধাজ্ঞা
Tolterodine Tartrate should not be used by patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, or by anyone who has shown hypersensitivity to Tolterodine Tartrate.